Skip to content
Triangle logo TriangleGet started
← Study library

NCT01822314 · CITED IN SOURCE DOCUMENTS

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2024-03-07

The purpose of this study is to assess the efficacy of neoadjuvant weekly nab-paclitaxel followed by Adriamycin, Cyclophosphamide (AC) or Epirubicin, Cyclophosphamide (EC) or Fluorouracil,Epirubicin,Cyclophosphamide (FEC)compared with neoadjuvant weekly solvent-based paclitaxel followed by AC or EC or FEC in terms of rate of pathological complete remissions at surgery.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Female patients aged 18 years or older * Histologically confirmed invasive unilateral breast cancer * HER2-negative disease * Known hormone receptor status (estrogen receptor \[ER\], progesterone receptor \[PgR\]), tumor grade and, if institutional standard permits, known Ki67 value * Available paraffin-embedded tumor block taken at diagnostic biopsy for central confirmation of HER2 eligibility, hormone receptor status, Ki67 value and biomarker evaluation is mandatory * One of the following clinical stages: * T2, T3, T4 disease, triple negative (HER2, ER, PgR) * T2, T3, T4 disease, ER or PgR positive and moderately differentiated or poorly differentiated tumor grade (G II-III) * ECOG performance status 0 or 1 * Written informed consent to participate in the trial (approved by the Institutional Review Board \[IRB\]/ Independent Ethics Committee \[IEC\]) obtained prior to any study specific screening procedures * Willing and able to comply with the protocol Exclusion Criteria: * Synchronous contralateral breast cancer or presence of metastatic disease (M1). Exception: contralateral insitu ductal cancer * Surgical axillary staging procedure prior to study entry. Exceptions: 1) Fine needle aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted * Pregnant or lactating women. * Women with childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception, for example abstinence, an intra-uterine device, or double barrier method of contraception * Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy for the currently diagnosed breast cancer prior to study entry * Previous investigational treatment for any condition within 4 weeks of randomization date * Patients on therapy with a strong CYP3A4 inhibitor and on therapy with Warfarin (Coumadin) * Previous or concomitant malignancy of any other type that could affect compliance with the protocol or interpretation of results. Patients with curatively treated basal cell carcinoma of the skin or in situ cervix cancer are generally eligible. * Pre-existing motor or sensory neuropathy of grade \> 1 for any reason * Patients with a history of hypersensitivity due to drugs containing polyoxyethylene castor oil (Cremophor EL) (e.g., ciclosporin), or hardened castor oil (e.g., vitamin preparations for injection, etc.) * Other serious illness or medical condition including: history of documented congestive cardiac failure; angina pectoris requiring anti-anginal medication; evidence of transmural infarction on ECG; poorly controlled hypertension (e.g. systolic \>180 mm Hg or diastolic \>100 mm Hg; however, patients with hypertension which is well controlled on medication are eligible); clinically significant valvular heart disease; high-risk uncontrolled arrhythmias * Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent or adversely affecting compliance with study drugs * Serious uncontrolled infections (bacterial or viral) or poorly controlled diabetes mellitus * Hematology and biochemistry tests within normla limits * Baseline left ventricular ejection fraction (LVEF) \< 50% by echocardiography or multi-gated scintigraphic scan (MUGA)
healthy Volunteers
false
minimum Age
18 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles. AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles
    intervention Names
    1. Drug: Paclitaxel
    label
    Paclitaxel
    type
    ACTIVE_COMPARATOR
  2. description
    Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles. AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles
    intervention Names
    1. Drug: Abraxane
    label
    Abraxane
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Abraxane
    description
    Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
    name
    Abraxane
    other Names
    1. Nab-paclitaxel
    type
    DRUG
  2. arm Group Labels
    1. Paclitaxel
    description
    Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
    name
    Paclitaxel
    other Names
    1. No specific brand name
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
632
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    To compare the rate of pathologic Complete Response (pCR, absence of invasive disease in breast and nodes (ypT0/ypTis, ypN0)) for abraxane (Abraxane®, abraxane) vs paclitaxel.
    measure
    pathologic Complete Response (pCR)
    time Frame
    At the time of surgery: 40 months after the randomization of the first patient
secondary Outcomes
  1. description
    To compare the rate of clinical overall response (cOR) after the first 4 cycles of abraxane vs paclitaxel and to compare the rate of cOR after the entire preoperative chemotherapy (i.e. before surgery) in the study arms of abraxane vs paclitaxel
    measure
    clinical Overall Response (cOR)
    time Frame
    At the time of surgery: 40 months after the randomization of the first patient
  2. description
    To compare the Event Free Survival (EFS, i.e. disease progression while on primary therapy or disease recurrence after surgery) in the study arms of abraxane vs paclitaxel
    measure
    Event Free Survival (EFS)
    time Frame
    5 years after the first patient in and 10 years after randomization of last patient in
  3. description
    The distant event free survival (DEFS) is defined as the time from randomization to the first date of distant metastasis while on primary therapy or distant recurrence after surgery or death due to any cause. Patients who terminate the study without evidence of any of the above events will be censored at the date of their last follow-up tumor assessment
    measure
    Distant Event Free Survival (DEFS)
    time Frame
    5 years after the first patient in and 10 years after randomization of last patient in
  4. description
    The local event free survival (LEFS) is defined as the time from randomization to the first date of local progression while on primary therapy or local recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS
    measure
    Local Event Free Survival
    time Frame
    5 years after the first patient in and 10 years after randomization of last patient in
  5. description
    The regional event free survival (REFS) is defined as the time from randomization to the first date of regional progression while on primary therapy or regional recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS.
    measure
    Regional Event Free Survival
    time Frame
    5 years after the first patient in and 10 years after randomization of last patient in
  6. description
    The overall survival (OS) is defined as the time from randomization to the date of death. Patients alive at the end of study will be censored at their last contact date.
    measure
    Overall Survival (OS)
    time Frame
    13 years from the date of first patient in
  7. description
    Patients will be assessed for adverse events by clinical examination, questioning for symptoms of toxicity, laboratory assessments, vital signs, ECG and LVEF. Neurological toxicity and other toxicities will be assessed throughout the study according the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0.
    measure
    Safety and Tolerability
    time Frame
    Each participant will be followed for the duration of treatment period, approximately 9 months
Full study description
brief Summary
The purpose of this study is to assess the efficacy of neoadjuvant weekly nab-paclitaxel followed by Adriamycin, Cyclophosphamide (AC) or Epirubicin, Cyclophosphamide (EC) or Fluorouracil,Epirubicin,Cyclophosphamide (FEC)compared with neoadjuvant weekly solvent-based paclitaxel followed by AC or EC or FEC in terms of rate of pathological complete remissions at surgery.
detailed Description
In this study, eligible and consenting patients will be randomized to receive either 4 cycles of weekly abraxane (nab-paclitaxel) followed by 4 cycles of an anthracycline-containing regimen or 4 cycles of weekly paclitaxel followed by 4 cycles of an anthracycline-containing regimen.The anthracycline regimen (AC, EC or FEC) will be chosen by the investigator at the participating sites. Before randomization patients will be stratified according to Disease stage \[operable (tumor stage: T2N0-1; T3N0) and locally advanced (T3N1;T4, any N2-3)\] and Tumor subtype \[luminal B intermediate (HER2 negative, ER or PGR positive, Ki67 from 14% to 20%) vs luminal B high (HER2 negative, ER or PGR positive, Ki67 \>20%) vs triple negative tumors (HER2 negative, ER negative and PgR negative, Ki67 any value)\]. Tumor subtype will be confirmed at two selected referral laboratories. Neoadjuvant chemotherapy will be followed by definite surgery and irradiation as per international and local guidelines. During neoadjuvant chemotherapy patients will be assessed for safety and efficacy as detailed in the protocol. After definite surgery patients will be followed for approximately 10 years according to local procedures
Source references
references
  1. citation
    Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzu D, De Fato R, Valagussa P, Tusquets I. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.
    pmid
    29327055
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-7057ed1c875bdcf9951a
      requested nct id
      NCT01822314
      primary nct id
      NCT01822314
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
      payload sha256
      73383fccb60c1cd17bff86ea0a30e390ed3d438c533f12ebddd34942a146e5d3
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-7057ed1c875bdcf9951a
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01822314
      occurrences
      1. context exact
        DR0000810031&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence B3</a>] </li><li>However, in the <a href="/clinicaltrials/NCT01822314">ETNA</a> trial (NCT01822314) that compared neoadjuvant nab-paclitaxel with paclitaxel followed by anthracycline-based therapy, no significant difference in pC
        end
        300427
        exact text
        NCT01822314
        start
        300416
      2. context exact
        thProfessional&amp;language=English'); return(false);">Level of evidence B3</a>] </li><li>However, in the <a href="/clinicaltrials/NCT01822314">ETNA</a> trial (NCT01822314) that compared neoadjuvant nab-paclitaxel with paclitaxel followed by anthracycline-based therapy, no significant difference in pCR was observed, and neutropen
        end
        300456
        exact text
        NCT01822314
        start
        300445
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
      source file sha256
      862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:35.419733+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
      source title
      Breast Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 25, 2025
        datetime
        2025-04-25T12:00:00Z
        display
        April 25, 2025

    Preserved source evidence · Not medical advice